Treating small blood vessel problems in type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether two different treatment strategies can improve the function of the tiny blood vessels in people with type 1 diabetes. It aims to find a way to prevent or reduce diabetes-related complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 diabetes and have had it for more than 5 years
- You are between 18 and 40 years old
- Your average blood sugar (HbA1c) is less than 8.5%
- Your body mass index (BMI) is between 19 and 34.9
- You use insulin (by injections or pump) as your only diabetes medicine
- You have not had any diabetes-related complications like kidney, eye, or nerve damage
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This study tests if combining exercise with a drug called liraglutide improves blood vessel health and insulin sensitivity in people with type 2 diabetes. It looks at whether these treatments work better together or alone.
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
This early study looks at how “autophagy” (your body’s cell recycling process) relates to small blood-vessel problems in people with type 2 diabetes. It may help researchers understand mechanisms and possible future treatments, mainly for people who meet specific health and medication criteria.
This study tests a new once-weekly injectable medication (HDM1005) for people with type 2 diabetes whose blood sugar is not well controlled by diet and exercise or metformin alone. It aims to help lower blood sugar and may also support weight loss.
This trial tests if newer diabetes medications can reduce heart risk and help achieve diabetes remission in people newly diagnosed with type 2 diabetes. It may be an option if you have not taken diabetes drugs before or stopped them over three months ago, and your blood sugar and weight are in certain ranges.
Hear when a new Endothelial Dysfunction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.